Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule precision medicines for CNS disorders, has announced its participation in two major healthcare conferences in November 2024. The company will engage in fireside chats at the Stifel Healthcare Conference in New York City on November 18 at 1:15pm ET, and the Jefferies London Healthcare Conference on November 20 at 4:00pm GMT/11am ET. Live and archived webcasts will be available on the company's investor relations website.
Rapport Therapeutics (Nasdaq: RAPP), un'azienda biotech in fase clinica che sviluppa medicinali di precisione a piccole molecole per disordini del SNC, ha annunciato la sua partecipazione a due importanti conferenze sanitarie nel novembre 2024. L'azienda parteciperà a discussioni informali alla Stifel Healthcare Conference a New York il 18 novembre alle 13:15 ET, e alla Jefferies London Healthcare Conference il 20 novembre alle 16:00 GMT/11:00 ET. Saranno disponibili webcast dal vivo e registrati sul sito web delle relazioni con gli investitori dell'azienda.
Rapport Therapeutics (Nasdaq: RAPP), una empresa biotecnológica en etapa clínica que desarrolla medicamentos de precisión a base de pequeñas moléculas para trastornos del SNC, ha anunciado su participación en dos importantes conferencias de salud en noviembre de 2024. La empresa participará en charlas informales en la Stifel Healthcare Conference en la ciudad de Nueva York el 18 de noviembre a la 1:15 p. m. ET, y en la Jefferies London Healthcare Conference el 20 de noviembre a las 4:00 p. m. GMT/11:00 a. m. ET. Las transmisiones web en vivo y grabadas estarán disponibles en el sitio web de relaciones con inversores de la empresa.
Rapport Therapeutics (Nasdaq: RAPP)는 CNS 장애를 위한 소분자 정밀 의약품을 개발하는 임상 단계의 생명공학 회사로, 2024년 11월에 두 개의 주요 의료 컨퍼런스에 참여한다고 발표했습니다. 회사는 뉴욕시에서 11월 18일 오후 1시 15분(동부 표준시)에 열리는 Stifel Healthcare Conference와 11월 20일 오후 4시(그리니치 표준시)/오전 11시(동부 표준시)에 열리는 Jefferies London Healthcare Conference에서 대화에 참여할 예정입니다. 실시간 및 아카이브 웹캐스트는 회사의 투자자 관계 웹사이트에서 이용할 수 있습니다.
Rapport Therapeutics (Nasdaq: RAPP), une entreprise biotechnologique en phase clinique développant des médicaments de précision à petites molécules pour les troubles du SNC, a annoncé sa participation à deux grandes conférences de santé en novembre 2024. L'entreprise participera à des discussions informelles lors de la Stifel Healthcare Conference à New York le 18 novembre à 13h15 ET, et à la Jefferies London Healthcare Conference le 20 novembre à 16h00 GMT/11h00 ET. Des webdiffusions en direct et des enregistrements seront disponibles sur le site web des relations avec les investisseurs de l'entreprise.
Rapport Therapeutics (Nasdaq: RAPP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das präzise Medikamente auf Basis kleiner Moleküle für CNS-Erkrankungen entwickelt, hat seine Teilnahme an zwei großen Gesundheitskonferenzen im November 2024 angekündigt. Das Unternehmen wird am 18. November um 13:15 Uhr ET an informellen Gesprächen auf der Stifel Healthcare Conference in New York City teilnehmen und am 20. November um 16:00 Uhr GMT/11:00 Uhr ET auf der Jefferies London Healthcare Conference vertreten sein. Live- und aufgezeichnete Webcasts werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows:
- The Stifel Healthcare Conference in New York City
Monday, November 18, 2024, at 1:15pm ET
- The Jefferies London Healthcare Conference
Wednesday, November 20, 2024, at 4:00pm GMT/11am ET
Interested parties may access the live and archived webcasts under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
Source: https://www.rapportrx.com/
FAQ
When is Rapport Therapeutics (RAPP) presenting at the Stifel Healthcare Conference in 2024?
What time is Rapport Therapeutics (RAPP) presenting at the Jefferies London Healthcare Conference?
Where can investors watch Rapport Therapeutics' (RAPP) conference presentations?
What type of medicines does Rapport Therapeutics (RAPP) develop?
